- Home
- HCWB vs BREA Comparison
HCWB vs BREA Comparison
Compare HCWB & BREA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWB
- BREA
- Stock Information
- Founded
- HCWB 2018
- BREA 2022
- Country
- HCWB United States
- BREA Ireland
- Employees
- HCWB N/A
- BREA N/A
- Industry
- HCWB Biotechnology: Pharmaceutical Preparations
- BREA Services-Misc. Amusement & Recreation
- Sector
- HCWB Health Care
- BREA Consumer Discretionary
- Exchange
- HCWB Nasdaq
- BREA Nasdaq
- Market Cap
- HCWB 16.1M
- BREA 13.6M
- IPO Year
- HCWB 2021
- BREA 2023
- Fundamental
- Price
- HCWB $4.44
- BREA $6.88
- Analyst Decision
- HCWB Strong Buy
- BREA
- Analyst Count
- HCWB 1
- BREA 0
- Target Price
- HCWB $35.00
- BREA N/A
- AVG Volume (30 Days)
- HCWB 236.1K
- BREA 18.5K
- Earning Date
- HCWB 08-13-2025
- BREA 01-03-2025
- Dividend Yield
- HCWB N/A
- BREA N/A
- EPS Growth
- HCWB N/A
- BREA N/A
- EPS
- HCWB N/A
- BREA N/A
- Revenue
- HCWB $1,445,145.00
- BREA $2,988,009.00
- Revenue This Year
- HCWB N/A
- BREA N/A
- Revenue Next Year
- HCWB N/A
- BREA N/A
- P/E Ratio
- HCWB N/A
- BREA N/A
- Revenue Growth
- HCWB N/A
- BREA 151.51
- 52 Week Low
- HCWB $3.55
- BREA $5.00
- 52 Week High
- HCWB $100.80
- BREA $19.50
- Technical
- Relative Strength Index (RSI)
- HCWB 28.61
- BREA 96.66
- Support Level
- HCWB $4.05
- BREA $0.66
- Resistance Level
- HCWB $5.77
- BREA $0.79
- Average True Range (ATR)
- HCWB 0.49
- BREA 0.20
- MACD
- HCWB -0.07
- BREA 0.39
- Stochastic Oscillator
- HCWB 9.98
- BREA 84.50
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.